AKT1 and prostate cancer: Fisetin demonstrates anti-metastatic properties by suppressing phosphoinositide 3-kinase/Akt [PI3K/Akt], NF-kB, and JNK signalling pathways in prostate cancer cells and human cervical cancer HeLa cells [4,16].